Awareness and control of hypertension and hypercholesterolaemia in France and Northern-Ireland

QJM: An International Journal of Medicine

Volumn 90, Issue 5, 1997, Pages 341-345

  Marques Vidal, P ^a   Evans, A E ^b   Cambou, J P ^a   Arveiler, D ^c   Luc, G ^d   Bingham, A ^e   Cambien, F ^f  

^a CHU PURPAN   (France)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c Lab d'Epidemiol et de S Pub   (France)

^d INSTITUT PASTEUR DE LILLE   (France)

^e HÔPITAL BROUSSAIS   (France)

^f INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYPOCHOLESTEROLEMIC AGENT;

ADULT; ARTICLE; FRANCE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; UNITED KINGDOM;

EID: 0030981121     PISSN: 00335622     EISSN: None     Source Type: Journal    
DOI: 10.1093/qjmed/90.5.341     Document Type: Article

References (28)

1. The Multiple Risk Factor Intervention Trial Research Group. Mortality rates after 10.5 years for participants in the Multiple Risk Factor Intervention Trial. JAMA 1990; 263:1795-801.
2. The West of Scotland Coronary Prevention Study Group. A coronary primary prevention study of Scottish men aged 45-64 years. J Clin Epidemiol 1992; 45:849-60.
3. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9.
4. Bush TL, Riedel D. Screening for total cholesterol. Circulation 1991; 83:1287-93.
5. Manson JE, Tosteson H, Ridker PM, Satterfield S, Hebert P, O'Connor GT, Buring JE, Hennekens CH. The primary prevention of myocardial infarction. N Engl J Med 1992; 326:1406-16.
6. Meredith PA. New FDA guidelines on the treatment of hypertension: comparison of different therapeutic classes according to trough/peak blood pressure responses. Arch Mal Coeur Vaiss 1994; 87:1423-9.
7. The Joint National Committee on Detection Evaluation and Treatment of High Blood Pressure. The 1984 report of the Joint Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1984; 144:1045-57.
8. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). JAMA 1993; 269:3015-23.
9. PyšrŠIŠ K, De Backer G, Graham I, Poole-Wilson P, Wood D, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice: recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994; 110:121-61.
10. Boissel JP, Némoz C, Gillet J, Salewski B, Diaz N. La prescription médicamenteuse dans le postinfarctus: résultats de l'EPPI (étude de prescription postinfarctus). Arch Mal Coeur Vaiss 1990; 83:1777-82.
11. Cohen MV, Byrne MJ, Levine B, Gutowsky T, Adelson R. Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease. Circulation 1991; 83:1294-304.
12. Schucker B, Wittes JT, Santanello NC, Weber SJ, McGoldrick D, Donato K, Levy A, Rifkind BM. Change in cholesterol awareness and action. Results from national physician and public surveys. Arch Intern Med 1991; 151:666-73.
13. Bostik RM, Luepker RV, Kofron PM, Pirie PL. Changes in physician practice for the prevention of cardiovascular disease. Arch Intern Med 1991; 151:478-84.
14. Stieber J, Hense HW, Döring A, Filipiak-Pitroff B, Tietze M, Gostomzyk J, Keil, U. Kardiovaskuläres risikofaktorenprofil. Verlaufsdaten aus der MONICA-studienregion Augsburg (1984/1985 vs. 1989/1990). Münch Med Wschr 1991; 133:370-5.
15. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population. Hypertension 1995; 25:305-13.
16. Parra HJ, Arveiler D, Evans A, Cambou JP, Amouyel P, Bingham A, McMaster D, Schaffer P, Douste-Blazy Ph, Luc G, Richard JL, Ducimetiere P, Fruchart JC, Cambien F. A case-control study of lipoprotein particles in two populations at contrasting risk for coronary heart disease. Arterioscler Thromb 1992; 12:701-7.
17. Cambien F, Costerousse O, Tiret L, Poirier O, Lecerf L, Gonzales MF, Evans A, Arveiler D, Cambou JP, Luc G, Rakotovao R, Ducimetiere P, Soubrier F, Alhenc-Gelas F. Plasma level and gene polymorphism of angiotensin-converting enzyme in relation to myocardial infarction. Circulation 1994; 90:669-76.
18. WHO MONICA Project (prepared by Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas A-M, Pajak A). Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates and case fatality rates in 38 populations from 21 countries in four continents. Circulation 1994; 90:583-612.
19. Petrie JC, O'Brien ET, Littler WA, De Swiet M. Recommendations on blood pressure measurement. Br Med J 1986; 293:611-5.
20. Smith WCS, Lee AJ, Crombie IK, Tunstall-Pedoe H. Control of blood pressure in Scotland: the rule of halves. Br Med J 1990; 300:981-3.
21. Wikstrand J, Warnold I, Olsson G, Tuomilehto J, Elmfeldt D, Berglund G; on behalf of the Advisory Committee. Primary prevention with metoprolol in patients with hypertension. JAMA 1988; 259:1976-82.
22. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomized drug trials in their epidemiological context. Lancet 1990; 335:827-38.
23. Monane M, Bohn RL, Gurwitz JH, Glynn RJ, Avorn J. Noncompliance with congestive heart failure therapy in the elderly. Arch Intern Med 1994; 154:433-7.
24. Komiya T, Kudo M, Urabe T, Mizuno Y. Compliance with antiplatelet therapy in patients with ischemic cerebrovascular disease. Stroke 1994; 25:2337-42.
25. Marques-Vidal P, Cambou JP, Evans A, Arveiler D, Luc G, Bingham A, Cambien F. Medical treatment of myocardial infarction in France and Northern Ireland: results from the ECTIM Study. Eur Heart J 1995; 16:348-53.
26. Conseil d'administration d'ARCOL. Consensus français sur le cholestérol et les dyslipoprotéinémies. Rev Prat 1989; 39:972-4.
27. Denke MA, Grundy SM. Individual responses to a cholesterol-lowering diet in 50 men with moderate hypercholesterolemia. Arch Intern Med 1994; 154:317-25.
28. Neaton JD, Grimm RH, Prineas RJ, Stamler J, Grandits GA, Elmer PJ, Cutler JA, Flack JM, Schoenberger JA, McDonald R, Lewis CE, Liebson PR: for the Treatment of Mild Hypertension Study Research Group. Treatment of Mild Hypertension Study. Final results. JAMA 1993; 270:713-24.